Sam O Pharmaceutical Increases Stake in Aminologics to 34.40% via Past Capital Increase and CB Acquisition

Sam O Pharmaceutical disclosed that its ownership stake in Aminologics increased from 16.67% at end-2013 to 34.40% as of June 30, 2025, through a 2015 third-party allotment of 14,574,524 shares and acquisition of the 4th series convertible bonds of 5,224,660 shares in 2025.
The conversion price of the CB is 957 KRW, representing a 4.7% premium over the current market price of 1,004 KRW.
Full conversion of the CB would result in additional dilution of approximately 5.95% of outstanding shares, potentially pressuring existing shareholder value.
As a major shareholder with over 10% stake, Sam O Pharmaceutical's move appears aimed at maintaining stable control rather than active management involvement.
[AI Summary]Sam O Pharmaceutical's gradual stake increase through past capital increase and CB acquisition has limited short-term impact, but the potential dilution from the outstanding CB warrants monitoring. The low conversion price relative to market may create arbitrage opportunities, though the major shareholder's long-term holding intent could support price stability.